Cordycepin

Cell lines

HeLa cells

Preparation method

The solubility of this compound in DMSO is >10.3 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

25 μg/ml, 30 min

Applications

Cordycepin (25 μg/ml) suppressed the labeling of messenger RNA in HeLa cells. Cordycepin inhibited NO production in a dose-dependent manner up to 30 μg/ml. In RAW 264.7 cells, treatment with cordycepin decreased LPS-induced synthesis of iNOS protein in a dose-dependent manner. Cordycepin significantly decreased the mRNA levels of TNF-α induced by LPS in a dose-dependent manner. Cordycepin (20 μg/ml) inhibited LPS-mediated IκBα phosphorylation in a dose-dependent manner in LPS-induced macrophage cell. Cordycepin decreased the phosphorylation level of p38 and Akt in LPS-stimulated cells in a concentration-dependent manner.

Animal models

Mice bearing B16 melanoma (B16-BL6) cells,

Dosage form

Oral administration, 15 mg/kg per day for 2 weeks

Application

Oral administration of cordycepin (15 mg/kg per day) for 2 weeks significantly reduced the wet weight of the primary tumour lump, without any loss of bodyweight or systemic toxicity. Cordycepin (15 mg/kg per day) inhibited the tumour enlargement in the right thigh inoculated with B16-BL6 cells premixed with extracellular matrix. In hematogenic metastatic mouse model bearing B16-BL6 melanoma cells, 3-hour exposure to various concentrations of cordycepin (0.3, 1 and 3 μg/ml) dose-dependently reduced the number of nodules formed in lung at 15 days after the tumor injection. Cordycepin did not influence the growth curve of B16-BL6 cells at concentrations up to 3 μg/ml.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Penman S, Rosbash M, Penman M. Messenger and heterogeneous nuclear RNA in HeLa cells: differential inhibition by cordycepin[J]. Proceedings of the National Academy of Sciences, 1970, 67(4): 1878-1885.

[2]. Kim H G, Shrestha B, Lim S Y, et al. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cells[J]. European journal of pharmacology, 2006, 545(2): 192-199.

[3]. Yoshikawa N, Nakamura K, Yamaguchi Y, et al. Antitumour activity of cordycepin in mice[J]. Clinical and Experimental Pharmacology and Physiology, 2004, 31(s2).

[4]. Nakamura K, KONOHA K, YOSHIKAWA N, et al. Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice[J]. in vivo, 2005, 19(1): 137-141.